Reference

Phosphonic acid esters and their use in flame-resistant finishing

Phosphonic acid esters and their use in flame-resistant finishing. Hendricks, Udo Winfried; Walz, Klaus; Schaefer, Karl (Bayer A.-G., Ger.). Ger. Offen. DE 2544550 14 Apr 1977, 34 pp. (German). (Germany). CODEN: GWXXBX. CLASS: IC: C07F009-40. APPLICATION: DE 75-2544550 4 Oct 1975. DOCUMENT TYPE: Patent CA Section: 39 (Textiles) Phosphonic acid esters with the formula RP(O)(OR1)(OR2) (R = Me, MeO2CCH2, NCCH2CH2, MeCO2(CH2)3 or CH2:CH; R1 = Me, Et, or 3,4-dichlorobenzyl; R2 = 3,4-dichlorobenzyl or benzyl) are prepd. and used as fireproofing agents for polyester textiles. Thus, 700 parts MeP(O)(OMe)(OCH2C6H3Cl2-3,4) (I) [63257-10-3] (prepd. by treating di-Me methanephosphonate [756-79-6] with 3,4-dichlorobenzoyl chloride [3024-72-4]) was mixed with 150 parts water and 150 parts Na dodecylbenzenesulfonate to give a liq compn. which could be mixed with water to form a stable emulsion. 20580-36-3 is the cas registry number of certain chemical which is used as reagents here. A poly(ethylene terephthalate) fabric (250 g) was heated 30 min at 125.degree. at goods-liquor ratio 1:15 in an aq. liquor contg. 8% I compn., 1.5% disperse dye, 2 g/L nonionic dispersing agent, and 1 g/L NaPO4. After treatment with an alk. Na dithionite soln., the fabric had durable flame retardancy and a soft hand. .

Novel 2-(Substituted phenyl)benzimidazole Derivatives with Potent Activity against IgE, Cytokines, and CD23 for the Treatment of Allergy and Asthma

Novel 2-(Substituted phenyl)benzimidazole Derivatives with Potent Activity against IgE, Cytokines, and CD23 for the Treatment of Allergy and Asthma. Richards, Mark L.In this study， 820242-70-4 and 3024-72-4 are also used.; Lio, Shirley Cruz; Sinha, Anjana; Tieu, Kenneth K.; Sircar, Jagadish C. (Avanir Pharmaceuticals, San Diego, CA 92121, USA). Journal of Medicinal Chemistry, 47(26), 6451-6454 (English) 2004 American Chemical Society. CODEN: JMCMAR. ISSN: 0022-2623. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 28 The effectiveness of the injectable anti-IgE antibody omalizumab has validated IgE as an important target for allergic diseases, thus spawning the development of small-mol. IgE inhibitors. Herein, a brief SAR is described for novel phenylbenzimidazole compds. that potently suppress IgE responses. In addn. to IgE, these agents inhibit other targets crit. for allergic response. The profile of orally active AVP-13358, the lead compd. of this series currently in clin. trials, is described. .